Semantic Coherence: Rapivab (BioCryst Pharmaceuticals) – Signal Evidence & AI Readability

[IMG: Rapivab]
[H3] See what makes Rapivab stand out as an antiviral influenza treatment

[H4] A FULL COURSE of ANTIVIRAL INFLUENZA TREATMENT IN

[H4] SHORTENED TIMEto alleviation of symptoms by a median of

[H5] In patients aged 6 months to 17 years, symptoms were resolved in a median of 79 hours vs. 100 hours for oseltamivir1

[H4] SHORTENED TIMEto resolution of fever by a median of

[H5] In patients aged 6 months to 17 years, fever was resolved in a median of 40 hours vs. 35 hours for oseltamivir1,2

[H1] It’s easy to access and order Rapivab

To order, please call 1-833-964-2956 if you are a US-based institution or health care professional.
ORDER RAPIVAB
References: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021. 2. Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568-4574. 3. BioCryst Pharmaceuticals, Inc. Summary of clinical efficacy. Data on file. 4. Managed Markets Insights & Technology, LLC website. https://formularylookup.com/. Accessed March 16, 2021.

[H1] Dosing &
Administration

[H3] One 15- to 30-minute intravenous (IV) infusion provides a full course of antiviral influenza treatment1
Use these dosing guidelines to determine the dosage of Rapivab® (peramivir injection) for your patients 6 months of age and older.

The administration of Rapivab in patients with renal impairment is at the discretion of the treating physician.

[H3] Preparation of Rapivab for IV infusion
Use aseptic technique during the preparation of Rapivab to prevent inadvertent microbial contamination. There is no preservative or bacteriostatic agent present in the solution.1
[H4] Follow the steps below to prepare a diluted solution of Rapivab1:

1. Do not use if seal over bottle opening is broken or missing.
2. Visually inspect Rapivab for particulate matter and discoloration prior to administration.
3. Dilute an appropriate dose of RAPIVAB 10 mg/mL solution [see Dosage and Administration (2.1, 2.2)] in 0.9% or 0.45% sodium chloride, 5% dextrose, or lactated Ringer’s. The maximum infusion volume is provided in Table 3. The final concentration of diluted RAPIVAB for administration should be between 1 mg/mL and 6 mg/mL.
4. Administer the diluted solution via intravenous infusion for 15 to 30 minutes.
5. Discard any unused diluted solution of Rapivab after 24 hours.
Once a diluted solution of Rapivab has been prepared, administer immediately or store under refrigerated conditions (2° to 8°C or 36° to 46°F) for up to 24 hours. If refrigerated, allow the diluted solution of Rapivab to reach room temperature, then administer immediately.
Do not use if seal over bottle opening is broken or missing.
Reference: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021.

[H1]    How
Supplied

[H3] Rapivab® (peramivir injection) is supplied in convenient single-use vials

Each single-use vial of Rapivab contains 200 mg per 20 mL (10 mg/mL) of peramivir in a clear glass vial (NDC #72769-181-01).1
Rapivab is supplied in cartons containing 3 single-use vials (NDC #72769-181-03).1

Reference: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021.

[H1] Coding
and Billing

[H3] Coding and billing information for Rapivab® (peramivir injection)
Use this information to facilitate coding and billing processes. Some payers will require the National Drug Code (NDC) code for Rapivab.1

[H3] Support and access for Rapivab

[H4] RAPIVAB CUSTOMER SUPPORT CENTER
1-833-964-2956 and rapivab.com

Current Procedural Terminology (CPT) Codes for Rapivab

The following CPT codes are for treatments administered via injection to individuals.

CPT Code 2
Description

96365
Intravenous (IV) infusion for therapy, prophylaxis, or diagnosis; initial, up to first hour

96366
IV med therapy−each additional hour

96374
IV med injection−first med

96375
IV med injection−second med subsequent injection

96376
IV med injection−first med subsequent injection

96360
IV hydration−first hour

96361
IV hydration−each additional hour

HCPCS Code 3
Description

J2547
Injection, peramivir, 1 mg

Report the administration of Rapivab in addition to the treatment product code
Assign the appropriate administration code based on the documentation in the medical record
Medicare requires the use of an HCPCS code for the administration of Rapivab. Some payers may also require that an HCPCS code be used to report Rapivab

Prior authorizations or appeals may not be completed or filed on the HCP's behalf.

Revenue codes for Rapivab

These codes are used to attribute hospital charges to specific cost centers. They may vary by service provided and patient status.

Revenue Code 4
Description

0636
Drugs requiring detailed coding required by Medicare to obtain pass-through payment for drugs in the outpatient department

0250
Pharmacy, general

0260
Intravenous therapy, general

0450
Emergency room

0510
Clinic

0520
IV hydration–first hour

ICD-10-CM codesa for Rapivab

Refer to these tables when you need the ICD-10-CM codes for Rapivab.

ICD-10 Code 5
Description

J10.00
Influenza due to other identified influenza virus with unspecified type of pneumonia

J10.01
Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia

J10.08
Influenza due to other identified influenza virus with other specified pneumonia

J11.00
Influenza due to unidentified influenza virus with unspecified type of pneumonia

J11.08
Influenza due to unidentified influenza virus with specified pneumonia

J12.9
Viral pneumonia, unspecified

J10.1
Influenza due to other identified influenza virus with other respiratory manifestations

J11.1
Influenza due to unidentified influenza virus with other respiratory manifestations

J10.2
Influenza due to other identified influenza virus with gastrointestinal manifestations

J10.81
Influenza due to other identified influenza virus with encephalopathy

J10.82
Influenza due to other identified influenza virus with myocarditis

J10.83
Influenza due to other identified influenza virus with otitis

J10.89
Influenza due to other identified influenza virus with other manifestations

J11.2
Influenza due to unidentified influenza virus with gastrointestinal manifestations

J11.81
Influenza due to unidentified influenza virus with encephalopathy

J11.82
Influenza due to unidentified influenza virus with myocarditis

J11.83
Influenza due to unidentified influenza virus with otitis media

J11.89
Influenza due to unidentified influenza virus with other manifestations

J09.X1
Influenza due to identified novel influenza A virus with pneumonia

J09.X2
Influenza due to identified novel influenza A virus with other respiratory manifestations

J09.X3
Influenza due to identified novel influenza A virus with gastrointestinal manifestations

J09.X9
Influenza due to identified novel influenza A virus with other manifestations

aThis may not be an all-inclusive list; see payor-specific coverage policies for covered indication.

References: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021. 2. Current Procedural Coding Expert; 2021 Chicago IL: Optum360; 2021. 3. Parman C. Hospital regulatory update. Association of Community Cancer Centers website. https://www.accc-cancer.org/oncology_issues/articles/JF16/JF16-Oncology-Coding-Reimbursement-Update.pdf. Accessed March 16, 2021. 4. CMS Manual System: Pub. 100-04 Medicare claims processing. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/r167cp.pdf. Published April 30, 2004. Accessed March 16, 2021. 5. Nelson M. ICD-10 cometh. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=5&cad=rja&uact=8&ved=0ahUKEwih4NKzjLfLAhXLTCYKHc2LAAUQFgg5MAQ&url=https%3A%2F%2Fwww.chestnet.org%2F~%2Fmedia%2Fchesnetorg%2FPublications%2FDocuments%2FCHEST%2520Physician%2FICD10InfluenzaCodes.ashx&usg=AFQjCNH5tCT-_gZ8SmRF_CZi0vB-OvUyFQ&sig2=JQocAaPEHmQ0wQsagrgHLQ&bvm=bv.116573086,d.cWw. Published April 2015. Accessed March 16, 2021.